Researchers at UCLA Health uncovered new information about the role inflammation plays in mitigating liver fibrosis, which is associated with metabolic-associated fatty liver disease (MAFLD), one of the most common diseases in the world affecting up to 40 percent of U.S. adults. While inflammation in the liver has long been considered a prerequisite to developing liver fibrosis, the scarring and thickening of tissue that can impair the liver’s ability to function, this new research suggests that reducing inflammation may not influence the extent of fibrosis.
SNAP Benefits and BP Meds; Post-PCI Anticoagulation Flop; CPAP’s Potential Harm
Receipt of Supplemental Nutrition Assistance Program benefits was associated with better adherence to antihypertensive medications. (JAMA Network Open) A new standard for chest protector equipment